- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Samsung Bioepis' Bevacizumab Is Cleared for Launch in Europe
Samsung Bioepis' latest approval gives it 5 biosimilar approvals in the European marketplace.
The European Commission (EC) has given marketing approval for the bevacizumab biosimilar Aybintio, by Samsung Bioepis.
The Incheon, Republic of Korea—based company said the EC has indicated the drug for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, non–small cell lung cancer, advanced or metastatic renal cell cancer, epithelial ovarian, fallopian tube and primary peritoneal cancer, and cervical cancer. These encompass all approved indications for the reference product, Avastin.
The company noted the drug was approved based on analytical, pharmacokinetic, and clinical data, as well as pharmacology and toxicology data, all of which demonstrated that Aybintio and the reference product are highly similar with no clinically meaningful differences.
“Approval of Aybintio provides another treatment option for patients with certain types of cancers, enabling wider access to those in need,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis, expressing pride in the drug authorization achievement.
Samsung Bioepis now has 5 biosimilars approved for use in Europe. These include Benepali (etanercept), Flixabi (infliximab), Ontruzant (trastuzumab), and Imraldi (adalimumab).
In June, Aybintio was recommended for approval by Europe's Committee for Medicinal Products for Human Use.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
